title: Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.
abstract: This study was initiated to evaluate the association of acute pancreatitis (AP) with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with diabetes in Japan. A retrospective cohort study of a large medical and pharmacy claims database was performed to compare the incidence of AP among those receiving DPP-4 inhibitors and those receiving other oral antidiabetic drugs. The incidence of all AP and hospitalizations for AP was similar between the two groups. Previous exposure to DPP-4 inhibitors did not affect occurrence of AP in patients on other oral antidiabetic drugs. The Kaplan-Meier curve for time to AP was similar between the two groups, and was not affected by previous exposure to DPP-4 inhibitors. The Cox proportional hazard models showed the incidence of AP was not significantly higher in those receiving DPP-4 inhibitors. Despite numerous, important limitations related to claims database-based analyses, our results indicate that there is no increased risk of AP with use of DPP-4 inhibitors among patients with diabetes in Japan.
authors.affiliation: Centre for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan; Center Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, Osaka, Japan; Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Japan.
authors.forename: D
authors.initials: D
authors.lastname: Yabe
authors.forename: H
authors.initials: H
authors.lastname: Kuwata
authors.forename: M
authors.initials: M
authors.lastname: Kaneko
authors.forename: C
authors.initials: C
authors.lastname: Ito
authors.forename: R
authors.initials: R
authors.lastname: Nishikino
authors.forename: K
authors.initials: K
authors.lastname: Murorani
authors.forename: T
authors.initials: T
authors.lastname: Kurose
authors.forename: Y
authors.initials: Y
authors.lastname: Seino
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000276:immunology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006264:Health Benefit Plans, Employee; D006760:Hospitalization; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000187:drug effects* / Q000276:immunology; D010195:Pancreatitis / Q000139:chemically induced* / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D012189:Retrospective Studies; D012306:Risk; D016019:Survival Analysis
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents
keywords: acute pancreatitis; claims database; dipeptidyl peptidase-4 inhibitor